{
    "clinical_study": {
        "@rank": "65511", 
        "arm_group": [
            {
                "arm_group_label": "Eravacycline IV and oral", 
                "arm_group_type": "Experimental", 
                "description": "Eravacycline 1.5 mg/kg IV q24h plus eravacycline 250 mg PO BID"
            }, 
            {
                "arm_group_label": "Levofloxacin", 
                "arm_group_type": "Active Comparator", 
                "description": "Levofloxacin 750 mg PO QD + placebo PO QD"
            }, 
            {
                "arm_group_label": "Eravacycline 1.5 mg/kg, plus eravacycline 200 mg PO", 
                "arm_group_type": "Experimental", 
                "description": "Eravacycline 1.5 mg/kg IV q24h plus eravacycline 200 mg PO BID"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to\n      Assess the Efficacy and Safety of Eravacycline Compared with Levofloxacin in Complicated\n      Urinary Tract Infections (cUTI)"
        }, 
        "brief_title": "Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections", 
        "condition": "Complicated Urinary Tract Infections (cUTI)", 
        "condition_browse": {
            "mesh_term": "Urinary Tract Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. Male and female subjects with either:\n\n             a. Pyelonephritis and normal urinary tract anatomy (no more than 30% of the total\n             population), OR b. cUTI with at least one of the following conditions associated with\n             a risk for developing cUTI: i. Indwelling urinary catheter ii. Urinary retention\n             (approximately 100 mL of residual urine after voiding) iii. Neurogenic bladder iv.\n             Partial obstructive uropathy (eg, nephrolithiasis, bladder stones, and ureteral\n             strictures) v. Azotemia of renal origin (not CHF or volume related) such that the\n             serum BUN is elevated (> 20 mg/dL) AND the serum BUN:creatinine ratio is < 15 vi.\n             Surgically modified or abnormal urinary tract anatomy (eg, bladder diverticula,\n             redundant urine collection system, etc.) EXCEPT surgery within the last month\n\n        Exclusion Criteria:\n\n          -  1. Concurrent use of non-study antibacterial drug therapy that would have a potential\n             effect on outcome evaluations in subjects with cUTI, including:\n\n               1. Subjects with a history of a levofloxacin-resistant urinary tract infection\n\n               2. Likely to receive ongoing antibacterial drug prophylaxis prior to the LPT visit\n                  (eg, subjects with vesiculo-ureteral reflux)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "840", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01978938", 
            "org_study_id": "TP-434-010"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Eravacycline IV and oral", 
                    "Eravacycline 1.5 mg/kg, plus eravacycline 200 mg PO"
                ], 
                "intervention_name": "Eravacycline", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Levofloxacin", 
                "intervention_name": "Levofloxacin", 
                "intervention_type": "Drug", 
                "other_name": "Levaquin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ofloxacin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92120"
                    }, 
                    "name": "San Diego Clinical Trials"
                }, 
                "investigator": {
                    "last_name": "Mohamed Bidair, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torrance", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90505"
                    }, 
                    "name": "Harbor-UCLA Medical Center"
                }, 
                "investigator": {
                    "last_name": "Brad Spellberg, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33606"
                    }, 
                    "name": "Tampa General Hospital"
                }, 
                "investigator": {
                    "last_name": "David Orban, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "31904"
                    }, 
                    "name": "Columbus Regional Research Institute"
                }, 
                "investigator": {
                    "last_name": "David Subich, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": ", MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Ohio State University Wexner Medical Center"
                }, 
                "investigator": {
                    "last_name": "Christian Jones, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections", 
        "overall_contact": {
            "email": "klloyd@tphase.com", 
            "last_name": "Kevin Lloyd", 
            "phone": "617-715-3589"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective is to demonstrate that eravacycline is non-inferior to levofloxacin in responder outcome (clinical and microbiological response vs failure) in the micro-ITT population at the Post-Treatment (PT) visit (defined as 6-8 days after the completion of therapy).\nNOTE: For the EMA, the primary analysis populations will be the microbiologically evaluable (ME) and clinically evaluable (CE) populations.", 
            "measure": "Clinical and microbiological response vs failure", 
            "safety_issue": "No", 
            "time_frame": "at the Post-Treatment (PT) visit (defined as 6-8 days after the completion of therapy)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01978938"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Tetraphase Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tetraphase Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}